News & Events

Simpson Thacher successfully guided client CSL Plasma, alongside other companies developing plasma therapies for the treatment of COVID-19, in obtaining a positive business review letter from the Antitrust Division of the U.S. Department of Justice (“DOJ”). The letter, dated January 12, 2021, stated that the DOJ would not challenge proposed efforts by those companies to assist the Biomedical Advanced Research and Development Authority in designing quality standards for collecting COVID-19 convalescent plasma.

According to the DOJ’s business review letter, the companies’ efforts offer unique procompetitive benefits under the circumstances presented by COVID-19 that outweigh any potential for anticompetitive harm. “This public-private collaboration will support innovation to develop life-saving medicines to treat COVID-19,” said Assistant Attorney General Makan Delrahim of the DOJ’s Antitrust Division.

The Simpson Thacher team includes Sara Razi and Nick Ingros.